Suppr超能文献

共聚无定形吲哚美辛-精氨酸片剂的固态性质和药物释放行为,并用 Kollicoat® Protect 进行包衣。

Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.

机构信息

Div. of Pharmaceutical Technology, Dept. of Chemistry, University of Hamburg, Bundesstraße 45, 20146 Hamburg, Germany.

Dept. of Pharmacy, University of Copenhagen, Universitetsparken 2, DK-2100, Denmark.

出版信息

Eur J Pharm Biopharm. 2017 Oct;119:150-160. doi: 10.1016/j.ejpb.2017.06.007. Epub 2017 Jun 8.

Abstract

A promising approach to improve the solubility of poorly water-soluble drugs and to overcome the stability issues related to the plain amorphous form of the drugs, is the formulation of drugs as co-amorphous systems. Although polymer coatings have been proven very useful with regard to tablet stability and modifying drug release, there is little known on coating co-amorphous formulations. Hence, the aim of the present study was to investigate whether polymer coating of co-amorphous formulations is possible without inducing recrystallization. Tablets containing either a physical mixture of crystalline indomethacin and arginine or co-amorphous indomethacin-arginine were coated with a water soluble polyvinyl alcohol-polyethylene glycol graft copolymer (Kollicoat® Protect) and stored at 23°C/0% RH and 23°C/75% RH. The solid state properties of the coated tablets were analyzed by XRPD and FTIR and the drug release behavior was tested for up to 4h in phosphate buffer pH 4.5. The results showed that the co-amorphous formulation did not recrystallize during the coating process or during storage at both storage conditions for up to three months, which confirmed the high physical stability of this co-amorphous system. Furthermore, the applied coating could partially inhibit recrystallization of indomethacin during drug release testing, as coated tablets reached a higher level of supersaturation compared to the respective uncoated formulations and showed a lower decrease of the dissolved indomethacin concentration upon precipitation. Thus, the applied coating enhanced the AUC of the dissolution curve of the co-amorphous tablets by about 30%. In conclusion, coatings might improve the bioavailability of co-amorphous formulations.

摘要

提高难溶性药物溶解度并克服药物无定形形式相关稳定性问题的一种很有前景的方法是将药物制成共无定形系统。虽然聚合物涂层在片剂稳定性和控制药物释放方面已被证明非常有用,但对于共无定形制剂的涂层知之甚少。因此,本研究的目的是研究在不诱导重结晶的情况下,是否可以对共无定形制剂进行聚合物涂层。含有结晶吲哚美辛和精氨酸的物理混合物或共无定形吲哚美辛-精氨酸的片剂用水溶性聚乙烯醇-聚乙二醇接枝共聚物(Kollicoat®Protect)进行涂层,并在 23°C/0%RH 和 23°C/75%RH 下储存。通过 X 射线粉末衍射(XRPD)和傅里叶变换红外光谱(FTIR)分析涂层片剂的固体状态特性,并在磷酸盐缓冲液 pH4.5 中测试药物释放行为长达 4 小时。结果表明,共无定形制剂在涂层过程中和在两种储存条件下储存长达三个月期间均未发生重结晶,这证实了该共无定形系统具有很高的物理稳定性。此外,所施加的涂层可以在药物释放测试期间部分抑制吲哚美辛的重结晶,因为与各自的未涂层制剂相比,涂层片剂达到了更高的过饱和度水平,并且在沉淀时溶解的吲哚美辛浓度下降较低。因此,所施加的涂层使共无定形片剂的溶解曲线 AUC 增加了约 30%。总之,涂层可能会提高共无定形制剂的生物利用度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验